| CTA | Canadian Tuberculosis Association; chemotactic activity; chromotropic acid; Committee on Thrombolyti... |
|---|---|
| NAHPA | National Association of Hospital Purchasing Agents |
| OHA | oral hypoglycemic agents |
| CINE | chemotherapy-induced nausea and emesis |
| RCT | radiotherapy and chemotherapy; randomized clinical trial; randomized controlled trial; registered ca... |
D factor
| salvage chemotherapy | Use of chemotherapy in a patient with recurrence of a malignancy following initial treatment, in hope of a cure or prolongation of life. Synonym: salvage therapy. (05 Mar 2000) |
|---|---|
| second line chemotherapy | <oncology> Chemotherapy given for a tumour which has already failed to respond to a first chemotherapy regimen (called first line). (16 Dec 1997) |
| induction chemotherapy | Use of chemotherapy as initial treatment before surgery or radiotherapy of a malignancy. (05 Mar 2000) |
| intensification chemotherapy | Repetitive cycles of treatment during the immediate post-remission period, used especially for leukaemia. Synonym: intensification chemotherapy. (05 Mar 2000) |
| intraperitoneal chemotherapy | Treatment in which anticancer drugs are put directly into the abdomen through a thin tube. (12 Dec 1998) |
| intrathecal chemotherapy | Treatment with drugs that are injected into the fluid surrounding the brain and spinal cort (cerebrospinal fluid). (12 Dec 1998) |
| topical chemotherapy | Treatment with anticancer drugs in a lotion or cream. (12 Dec 1998) |
| abortifacient agents | Chemical substances that interrupt pregnancy after implantation. (12 Dec 1998) |
| abortifacient agents, non-steroidal | Non-steroidal chemical compounds with abortifacient activity. (12 Dec 1998) |
| abortifacient agents, steroidal | Steroidal compounds with abortifacient activity. (12 Dec 1998) |
| adrenergic agents | Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters. (12 Dec 1998) |
| alkylating agents | Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agent, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (12 Dec 1998) |
| anti-allergic agents | Agents that are used to treat allergic reactions. most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (12 Dec 1998) |
| anti-anxiety agents | Agents that alleviate anxiety, tension, and neurotic symptoms, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. Some are also effective as anticonvulsants, muscle relaxants, or anaesthesia adjuvants. Adrenergic beta-antagonists are commonly used in the symptomatic treatment of anxiety but are not included here. Substances with a benzodiazepine ring structure widely used to treat anxiety and neuroses. Drugs in this class also generally have sedative or weak hypnotic properties and may be effective as muscle relaxants, anticonvulsants, and anaesthesia adjuvants. (12 Dec 1998) |
| anti-arrhythmia agents | Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (12 Dec 1998) |